Compare ARQT & FOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | FOUR |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | 2020 | 2020 |
| Metric | ARQT | FOUR |
|---|---|---|
| Price | $25.67 | $43.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 25 |
| Target Price | $39.13 | ★ $52.36 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $376,072,000.00 | ★ $4,180,000,000.00 |
| Revenue This Year | $43.21 | $22.37 |
| Revenue Next Year | $29.18 | $13.26 |
| P/E Ratio | $346.22 | ★ $27.53 |
| Revenue Growth | ★ 91.34 | 25.50 |
| 52 Week Low | $19.30 | $34.56 |
| 52 Week High | $34.80 | $75.35 |
| Indicator | ARQT | FOUR |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 62.16 |
| Support Level | $23.42 | $40.04 |
| Resistance Level | $28.54 | $46.17 |
| Average True Range (ATR) | 1.50 | 2.39 |
| MACD | -0.68 | 0.70 |
| Stochastic Oscillator | 4.63 | 90.57 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.